Target intelligence / Profile preview

Hyperopic peripheral defocus (None (no common abbreviation))

Target
None (no common abbreviation)
Molecular classification
Other (optical phenomenon; not a molecule or protein)
01

Overview

Hyperopic peripheral defocus refers to a condition where light rays entering the eye are focused behind the peripheral retina, while the central rays may be properly focused on the retina. This effect is commonly seen in myopic eyes corrected by traditional glasses or contact lenses, where peripheral rays focus farther back than the central rays. Extensive research, especially by Dr. Earl Smith and other groups, suggests that the presence of peripheral hyperopic defocus may signal the eye to continue growing axially (getting longer), which in turn leads to myopia progression in children. New strategies to slow myopia progression commonly use specially designed optical devices (multifocal contact lenses, progressive spectacle lenses, orthokeratology) to produce peripheral myopic defocus, redirecting the peripheral light rays to focus in front of the retina, thereby discouraging excessive eye growth. Hyperopic peripheral defocus is thus an optical risk factor or modulator in eye development, not a molecular therapeutic target. It is incorrectly classified as a "target molecule/receptor" in the context of therapeutic drug or molecular research.

Other names
Peripheral hyperopic defocusRelative peripheral hyperopic blur
02

Mechanism of action

Not applicable; but optical interventions (multifocal contact lenses, specialized eyeglasses, orthokeratology) target and correct peripheral defocus to slow myopia progression

03

Biological functions

Modulates axial eye growthInfluences emmetropization (normalization of eye growth and refraction during development)Contributes to the development/progression of myopia when present in the peripheral retina
04

Disease associations

Myopia progressionHyperopia and anisohyperopia (in context of interventions or study)
05

Safety considerations

Not direct for the phenomenon; safety and efficacy concern relates to efficacy of optical interventions, risk of insufficient myopia control, or visual comfort/quality
06

Biomarkers

Changes in peripheral refractive error (e.g., relative peripheral hyperopia)Axial eye length measurements

Beyond the preview

Go deeper on Hyperopic peripheral defocus (None (no common abbreviation)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hyperopic peripheral defocus (None (no common abbreviation)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call